2. Search Result
Search Result
Results for "

NOD-SCID mice

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-149428
    AD4
    1 Publications Verification

    		 PROTACs Cancer
    AD4 is an artemisinin derivative that is a proteolytic targeting chimera (PROTAC) targeting PCLAF. AD4 can effectively degrade PCLAF in RS4;11 cells (IC50: 0.6 nM), thereby activating the p21/Rb axis and exerting anti-tumor activity. AD4 also prolonged survival of RS4;11-transplanted NOD/SCID mice, with in vivo efficacy .
    AD4
  • HY-174437
    FLT3-IN-32

    		FLT3 Apoptosis Cancer
    FLT3-IN-32 is a potent and orally active FLT3 inhibitor. FLT3-IN-32 shows high selectivity for FLT3 and efficiently inhibits FLT3-activating mutations and induces apoptosis. FLT3-IN-32 shows good tolerability in non-tumor bearing mice. FLT3-IN-32 demonstrates outstanding anti-tumor efficacy in MV4-11 bearing NOD/SCID mice, prolonging the survival noticeably. FLT3-IN-32 can be used for the research of acute myeloid leukemia .
    FLT3-IN-32
  • HY-172617
    APD-94

    		BMI1 Microtubule/Tubulin Apoptosis Cancer
    APD-94 is a dual inhibitor targeting tubulin and Bmi-1. APD-94 interfers tubulin normal polymerization. APD-94 suppresses the expression of Bmi-1. APD-94 causes cell cycle arrest at the G2/M phase in cancer cells and induces apoptosis, thus inhibiting cancer cell proliferation. APD-94 represses the growth of HT29 cell xenografts in NOD/SCID mice. APD-94 can be used for colorectal cancer study .
    APD-94
  • HY-175541
    TQ-3959

    		PROTACs Btk Cancer
    TQ-3959 is an orally active BTK PROTAC degrader, with a DC50 of 14.6 nM. TQ-3959 exerts antiproliferative activity against both wild-type BTK and C481S mutant BTK cell lines. TQ-3959 exhibits tumor growth inhibition in female NOD-SCID mice bearing TMD-8 xenografts. TQ-3959 can be used in the research on B-cell malignancies such as lymphoma.(Pink: BTK ligand (HY-150885), Blue: CRBN Ligand (HY-W733888), Black: Linker (HY-W061884), E3 ligase ligand-linker conjugate (HY-175545)) .
    TQ-3959
  • HY-161494
    XYD190

    		PROTACs Epigenetic Reader Domain Cancer
    XYD190 (Compound 14g) is an orally active degrader for CBP/p300. XYD190 inhibits CBP/p300 bromodomain with IC50 of 483.7 nM. XYD190 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161496)) .
    XYD190
  • HY-161498
    XYD198

    		PROTACs Epigenetic Reader Domain Cancer
    XYD198 (Compound 14h) is an orally active degrader for CBP/p300. XYD198 inhibits CBP/p300 bromodomain with IC50 of 213.5 nM. XYD198 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161499))
    XYD198
  • HY-161497
    Thalidomide-benzylamine-Py-NH2

    		E3 Ligase Ligand-Linker Conjugates Cancer
    Thalidomide-benzylamine-Py-NH2 is a conjugate of E3 ligase ligand and linker, which is consisted of a Thalidomide (HY-14658) and the Linker Boc-NHCH2-Ph-Py-NH2 (HY-161496). Thalidomide-benzylamine-Py-NH2 is utilized for synthesis of PROTAC molecule XYD190 (HY-161494) .
    Thalidomide-benzylamine-Py-NH2
  • HY-161500
    Thalidomide-NHCH2-Ph-pyrimidine-NH2

    		E3 Ligase Ligand-Linker Conjugates Cancer
    Thalidomide-NHCH2-Ph-pyrimidine-NH2 is a conjugate of E3 ligase ligand and linker, which is consisted of a Thalidomide (HY-14658) and a Linker Boc-NHCH2-Ph-pyrimidine-NH2 (HY-161499). Thalidomide-NHCH2-Ph-pyrimidine-NH2 is utilized for synthesis of PROTAC molecule XYD198 (HY-161498) .
    Thalidomide-NHCH2-Ph-pyrimidine-NH2
  • HY-161496
    Boc-NHCH2-Ph-Py-NH2

    		PROTAC Linkers Cancer
    Boc-NHCH2-Ph-Py-NH2 is the linker for PROTAC molecule XYD190 (HY-161494) .
    Boc-NHCH2-Ph-Py-NH2
  • HY-161495
    CBP/p300 ligand 4

    		Ligands for Target Protein for PROTAC Epigenetic Reader Domain Cancer
    CBP/p300 ligand 4 (Compound 4) is an orally active inhibitor for CBP/p300 bromodomain, with IC50 of 91.4 nM. CBP/p300 ligand 4 serves as a ligand for target protein XYD190 (HY-161495). XYD190 is a PROTAC degrader for CBP/p300 .
    CBP/p300 ligand 4
  • HY-161499
    Boc-NHCH2-Ph-pyrimidine-NH2

    		PROTAC Linkers Cancer
    Boc-NHCH2-Ph-pyrimidine-NH2 is the linker for PROTAC molecule XYD198 (HY-161498) .
    Boc-NHCH2-Ph-pyrimidine-NH2
  • HY-161409
    SC912

    		Androgen Receptor Apoptosis Cancer
    SC912 is an AR-V7 inhibitor (IC50 = 0.36 μM). SC912 possesses safety, potency and selectivity. SC912 binds directly to AR-FL and AR-V7 proteins, inhibites nuclear localization and chromatin binding capabilities. SC912 exerts anticancer activity through inhibition of proliferation, induction of cell cycle arrest and apoptosis .
    SC912
  • HY-175610
    PROTAC FLT3/JAK2/BRD4 Degrader-1

    		PROTACs FLT3 JAK Epigenetic Reader Domain Cancer
    PROTAC FLT3/JAK2/BRD4 Degrader-1 is a PROTAC degrader that target FLT3, JAK2, and BRD4 with DC50 values of 5.23, 0.678, and 1.17 nM, respectively. PROTAC FLT3/JAK2/BRD4 Degrader-1 exhibits potent antiproliferative activity against MV4;11 cells (IC50 = 0.79 nM) and FLT3 mutant-transformed Ba/F3 cells. PROTAC FLT3/JAK2/BRD4 Degrader-1 induces apoptosis in MV4;11 cells. PROTAC FLT3/JAK2/BRD4 Degrader-1 demonstrates significant anti-tumor efficacy in the MV4;11 xenograft model established in NOD SCID mice. PROTAC FLT3/JAK2/BRD4 Degrader-1 can be used for the study of acute myeloid leukemia (AML). (Pink: FLT3/JAK2/BRD4 ligand (HY-175611), Blue: CRBN Ligand (HY-W087383), Black: Linker, E3 ligase ligand-linker conjugate (HY-W897939)) .
    PROTAC FLT3/JAK2/BRD4 Degrader-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: